US · BBIO · BIOTECHNOLOGY
BridgeBio Pharma, Inc. (BBIO) intrinsic value and stock valuation
$76.03as of 2026-11-21 · Mkt cap 16.06B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BridgeBio Pharma, Inc. DCF and intrinsic value
InvestorsCraft values BBIO with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from BBIO’s statements →
BridgeBio Pharma, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Revolution Medicines, Inc. (RVMD) $161.20
- Roivant Sciences Ltd. (ROIV) $38.66
- Moderna, Inc. (MRNA) $195.00
- Jazz Pharmaceuticals plc (JAZZ) $230.26
- Ascendis Pharma A/S (ASND) $252.73
- Exelixis, Inc. (EXEL) $64.63
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Summit Therapeutics Inc. (SMMT) $9.95
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.7M | $69.7M |
| Operating income | -$-569.09M | -$-592.97M | -$-607.37M | -$-512.2M | -$-576.63M |
| Net income | -$-729.31M | -$-535.76M | -$-643.2M | -$-481.18M | -$-562.54M |
| EPSd | -$-3.7M | -$-2.88M | -$-3.95M | -$-3.26M | -$-3.9M |
| Operating cash flow | -$-445.91M | -$-520.73M | -$-527.72M | -$-419.49M | -$-497.93M |
| Capital expenditure | -$-1.1M | -$-930K | -$-1.31M | -$-6.32M | -$-48.25M |
| Free cash flow | -$-447.01M | -$-521.66M | -$-529.03M | -$-425.81M | -$-546.18M |
| Total assets | $936M | $919.3M | $546.4M | $623M | $1.01B |
| Total debt | $2.73B | $1.73B | $1.74B | $1.72B | $1.73B |
| Net debt | $2.16B | $1.05B | $1.36B | $1.35B | $1.33B |
| Total equity | -$-2.08B | -$-1.46B | -$-1.34B | -$-1.24B | -$-865.58M |
| Cash and short-term investments | $587.5M | $681.1M | $434.9M | $471.9M | $836.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.7M | $69.7M |
| Cost of revenue | $28.3M | $3.88M | $2.45M | $3.43M | $3.11M |
| Gross profit | $473.8M | $218M | $6.86M | $74.2M | $66.6M |
| Research and development expenses | $477.5M | $506.5M | $455.7M | $399.5M | $451M |
| Selling, general and administrative expenses | $555.1M | $288.9M | $150.6M | $143.2M | $192.2M |
| Other expenses | $10.2M | $15.6M | $7.93M | $43.8M | $0.00 |
| Operating expenses | $1.04B | $811M | $614.2M | $586.4M | $643.2M |
| Cost and expenses | $1.07B | $814.9M | $616.7M | $589.9M | $646.4M |
| Interest income | $19.9M | $17.3M | $18M | $7.54M | $1.13M |
| Interest expense | $53.1M | $99.3M | $81.3M | $80.4M | $46.8M |
| Depreciation and amortization | $9M | $6.08M | $6.49M | $6.77M | $5.84M |
| Ebitda | -$-672.88M | -$-436.83M | -$-565.47M | -$-397.44M | -$-533.83M |
| Operating income | -$-569.09M | -$-592.97M | -$-607.37M | -$-512.2M | -$-576.63M |
| Total other income/expenses, net | -$-165.9M | $50.8M | -$-45.88M | $27.6M | -$-9.82M |
| Income before tax | -$-734.99M | -$-542.19M | -$-653.25M | -$-484.65M | -$-586.45M |
| Income tax expense | $560K | $1.15M | $0.00 | $0.00 | $0.00 |
| Net income | -$-729.31M | -$-535.76M | -$-643.2M | -$-481.18M | -$-562.54M |
| Weighted average shares outstanding | $197.2M | $186.1M | $162.8M | $147.5M | $144.4M |
| Weighted average diluted shares outstanding | $197.2M | $186.1M | $162.8M | $147.5M | $144.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $587.5M | $681.1M | $434.9M | $471.9M | $836.7M |
| Net receivables | $139.4M | $4.72M | $1.75M | $17.1M | $19.8M |
| Inventory | $26.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $753.7M | $720.7M | $477.6M | $548.9M | $888.9M |
| Property, plant and equipment, net | $13.5M | $12.8M | $19.8M | $25.3M | $46M |
| Goodwill and intangible assets | $28.1M | $23.9M | $26.3M | $28.7M | $44.9M |
| Long-term investments | $81.4M | $143.8M | $3.74M | $2.87M | $2.42M |
| Total non-current assets | $41.6M | $198.7M | $68.8M | $74.2M | $123.9M |
| Total assets | $936M | $919.3M | $546.4M | $623M | $1.01B |
| Accounts payable | $36.2M | $9.62M | $10.7M | $11.6M | $11.9M |
| Short-term debt | $17.4M | $4.51M | $4.13M | $3.67M | $4.94M |
| Deferred revenue | $20.3M | $0.00 | $6.1M | $8.16M | $0.00 |
| Total current liabilities | $288M | $154.4M | $143.8M | $121.4M | $135.1M |
| Long-term debt | $2.71B | $1.73B | $1.74B | $1.72B | $1.72B |
| Deferred revenue, non-current | $13.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.72B | $2.22B | $1.75B | $1.75B | $1.74B |
| Capital lease obligations | $3.81M | $9.2M | $13.1M | $16M | $22.4M |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B |
| Common stock | $200K | $200K | $180K | $160K | $150K |
| Retained earnings | -$-3.82B | -$-3.1B | -$-2.56B | -$-1.92B | -$-1.44B |
| Accumulated other comprehensive income (loss) | $10K | $10K | $30K | -$-330K | -$-130K |
| Total equity | -$-2.08B | -$-1.46B | -$-1.34B | -$-1.24B | -$-865.58M |
| Total investments | $98.8M | $143.8M | $62.7M | $98.1M | $445.3M |
| Total debt | $2.73B | $1.73B | $1.74B | $1.72B | $1.73B |
| Net debt | $2.16B | $1.05B | $1.36B | $1.35B | $1.33B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-724.93M | -$-543.35M | -$-643.2M | -$-484.65M | -$-586.45M |
| Depreciation and amortization | $5.97M | $6.08M | $6.49M | $6.77M | $5.84M |
| Stock-based compensation | $133M | $95.8M | $0.00 | $91.6M | $99.5M |
| Change in working capital | -$-51.06M | $32M | $5.06M | $28.1M | -$-4.4M |
| Accounts receivable | -$-134.72M | -$-2.97M | $15.3M | $15.2M | -$-19.75M |
| Inventory | -$-25.31M | $0.00 | $0.00 | $0.00 | $19.8M |
| Accounts payable | $26.6M | $1.51M | $2.78M | -$-350K | $2.83M |
| Net cash provided by operating activities | -$-445.91M | -$-520.73M | -$-527.72M | -$-419.49M | -$-497.93M |
| Investments in property, plant and equipment | -$-1.1M | -$-930K | -$-1.31M | -$-4.82M | -$-48.25M |
| Acquisitions, net | $0.00 | -$-140K | $0.00 | $0.00 | -$-35M |
| Net cash used for investing activities | -$-24.49M | $60.8M | $54M | $453.2M | -$-200.83M |
| Common stock issued | $34.2M | $314.7M | $449.8M | $4.85M | $0.00 |
| Common stock repurchased | -$-48.28M | -$-7.53M | -$-6.88M | -$-1.56M | -$-204.75M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $359.3M | $748.5M | $451.5M | -$-13.13M | $736.5M |
| Net change in cash | -$-111.1M | $288.5M | -$-22.15M | $20.5M | $37.7M |
| Cash at end of period | $572.1M | $683.2M | $394.7M | $416.9M | $396.4M |
| Operating cash flow | -$-445.91M | -$-520.73M | -$-527.72M | -$-419.49M | -$-497.93M |
| Capital expenditure | -$-1.1M | -$-930K | -$-1.31M | -$-6.32M | -$-48.25M |
| Free cash flow | -$-447.01M | -$-521.66M | -$-529.03M | -$-425.81M | -$-546.18M |
Line items
Line items
Line items
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
- CEO
- Neil Kumar
- Employees
- 839
- Beta
- 0.95
Explore
Frequently asked questions
What is the intrinsic value of BridgeBio Pharma, Inc. (BBIO)?
BridgeBio Pharma, Inc. (BBIO) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BBIO undervalued?
BBIO trades at a price of $76.03 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.